Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial

Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer

Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.

The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.

Inclusion Criteria:

• Proof of cT1a/b - 2a/b N0M0 NSCLC
• Informed Consent signed
• Resectable tumour
• Operable patient
• > 18 years old
• men and women